Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash-to-Debt 0.24
OMCL's Cash-to-Debt is ranked lower than
89% of the 1995 Companies
in the Global Health Information Services industry.

( Industry Median: 4.27 vs. OMCL: 0.24 )
Ranked among companies with meaningful Cash-to-Debt only.
OMCL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: No Debt Max: No Debt
Current: 0.24
0.04
No Debt
Equity-to-Asset 0.59
OMCL's Equity-to-Asset is ranked lower than
54% of the 1912 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. OMCL: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
OMCL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.57  Med: 0.64 Max: 0.78
Current: 0.59
-0.57
0.78
Debt-to-Equity 0.30
OMCL's Debt-to-Equity is ranked lower than
57% of the 1183 Companies
in the Global Health Information Services industry.

( Industry Median: 0.27 vs. OMCL: 0.30 )
Ranked among companies with meaningful Debt-to-Equity only.
OMCL' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.43  Med: 0.07 Max: 0.59
Current: 0.3
-0.43
0.59
Debt-to-EBITDA 2.02
OMCL's Debt-to-EBITDA is ranked lower than
65% of the 1040 Companies
in the Global Health Information Services industry.

( Industry Median: 1.30 vs. OMCL: 2.02 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OMCL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.02  Med: 3.79 Max: 3.92
Current: 2.02
2.02
3.92
Interest Coverage 5.08
OMCL's Interest Coverage is ranked lower than
87% of the 1497 Companies
in the Global Health Information Services industry.

( Industry Median: 138.02 vs. OMCL: 5.08 )
Ranked among companies with meaningful Interest Coverage only.
OMCL' s Interest Coverage Range Over the Past 10 Years
Min: 0.77  Med: 196.96 Max: 2680.5
Current: 5.08
0.77
2680.5
Piotroski F-Score: 8
Altman Z-Score: 5.01
Beneish M-Score: -2.35
WACC vs ROIC
8.94%
8.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating Margin % 5.32
OMCL's Operating Margin % is ranked lower than
53% of the 1940 Companies
in the Global Health Information Services industry.

( Industry Median: 5.13 vs. OMCL: 5.32 )
Ranked among companies with meaningful Operating Margin % only.
OMCL' s Operating Margin % Range Over the Past 10 Years
Min: 0.8  Med: 6.75 Max: 11.25
Current: 5.32
0.8
11.25
Net Margin % 6.11
OMCL's Net Margin % is ranked higher than
57% of the 1940 Companies
in the Global Health Information Services industry.

( Industry Median: 3.84 vs. OMCL: 6.11 )
Ranked among companies with meaningful Net Margin % only.
OMCL' s Net Margin % Range Over the Past 10 Years
Min: 0.09  Med: 4.64 Max: 6.92
Current: 6.11
0.09
6.92
ROE % 8.52
OMCL's ROE % is ranked higher than
53% of the 1869 Companies
in the Global Health Information Services industry.

( Industry Median: 6.75 vs. OMCL: 8.52 )
Ranked among companies with meaningful ROE % only.
OMCL' s ROE % Range Over the Past 10 Years
Min: 0.14  Med: 4.78 Max: 8.52
Current: 8.52
0.14
8.52
ROA % 4.70
OMCL's ROA % is ranked higher than
55% of the 2005 Companies
in the Global Health Information Services industry.

( Industry Median: 3.19 vs. OMCL: 4.70 )
Ranked among companies with meaningful ROA % only.
OMCL' s ROA % Range Over the Past 10 Years
Min: 0.08  Med: 3.47 Max: 5.8
Current: 4.7
0.08
5.8
ROC (Joel Greenblatt) % 23.41
OMCL's ROC (Joel Greenblatt) % is ranked lower than
52% of the 1965 Companies
in the Global Health Information Services industry.

( Industry Median: 23.66 vs. OMCL: 23.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OMCL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.43  Med: 41.98 Max: 64.63
Current: 23.41
2.43
64.63
3-Year Revenue Growth Rate 15.40
OMCL's 3-Year Revenue Growth Rate is ranked higher than
73% of the 1650 Companies
in the Global Health Information Services industry.

( Industry Median: 6.00 vs. OMCL: 15.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OMCL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.3  Med: 11.3 Max: 20.9
Current: 15.4
-53.3
20.9
3-Year EBITDA Growth Rate -8.10
OMCL's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 1466 Companies
in the Global Health Information Services industry.

( Industry Median: 8.90 vs. OMCL: -8.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OMCL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.5 Max: 130.8
Current: -8.1
0
130.8
3-Year EPS without NRI Growth Rate -13.90
OMCL's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 1339 Companies
in the Global Health Information Services industry.

( Industry Median: 10.60 vs. OMCL: -13.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OMCL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7.6 Max: 260.9
Current: -13.9
0
260.9
GuruFocus has detected 4 Warning Signs with Omnicell Inc OMCL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OMCL's 30-Y Financials

Financials (Next Earnings Date: 2019-02-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income
» OMCL's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades

OMCL Guru Trades in

Q1 2018

OMCL Guru Trades in Q1 2018

Mariko Gordon Sold Out
Ken Fisher 450,562 sh (-15.08%)
» More
Q2 2018

OMCL Guru Trades in Q2 2018

Ken Fisher 432,918 sh (-3.92%)
» More
Q3 2018

OMCL Guru Trades in Q3 2018

Ken Fisher 436,101 sh (+0.74%)
» More
» Details

Insider Trades

Financial Reports

Latest Guru Trades with OMCL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Select Gurus category: |Basic |Premium Premium Tools | Premium Plus Premium Plus | Modify your Personalized List of Gurus
Guru Date Action
 Impact Price Range
(Average)*		 Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Health Information Services    NAICS: 621999    SIC: 8099
Compare:NAS:INOV, NAS:PINC, HKSE:02666, SZSE:300451, NYSE:EVH, NAS:QSII, XTER:COP, NAS:TRHC, NAS:RCM, NAS:HSTM, NYSE:TDOC, LSE:EMIS, LSE:CRW, ASX:PME, SZSE:300550, XPAR:CGM, TSE:3902, SHSE:603990, TSE:4820, NAS:CPSI » details
Traded in other countries:OC9.Germany,
Headquarter Location:USA
Omnicell Inc provides automation and business analytics software solutions for patient-centric medication and supplies management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing.

Omnicell provides automation and business analytics software for healthcare providers. The firm operates in two segments: automation and analytics and medication adherence. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. This segment contributes the majority of revenue. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.

Top Ranked Articles about Omnicell Inc

Omnicell To Present At The 37th Annual J.P. Morgan Healthcare Conference
December 27, 2018
Read more...
Northeast Georgia Health System Selects Omnicell Automated Medication Management Platform to Support Newly Redesigned Pharmacy
December 5, 2018
Read more...
Omnicell Launches Vision for Fully Digitized, Autonomous Pharmacy at Annual ASHP Midyear Meeting
December 3, 2018
Read more...
Omnicell To Present At The 30th Annual Piper Jaffray Healthcare Conference
November 14, 2018
Read more...
Omnicell to Release Third Quarter 2018 Earnings Results on October 25, 2018
October 18, 2018
Read more...
Augusta University Health Selects Omnicell's Industry-Leading Medication Management Portfolio to Support Newly Redesigned Pharmacy
October 10, 2018
Read more...
Middlesex Hospital Bolsters Pharmacy Safety and Compliance by Extending Wolters Kluwer's Simplifi 797 with Omnicell's IVX Workflow
September 18, 2018
Read more...
Rob Seim to retire and join Omnicell Board of Directors
September 14, 2018
Read more...
Innovations to Omnicell Patient Engagement Platform Support Value-Based, Patient-Centered Care
August 23, 2018
Read more...
Omnicell Exhibits Industry-Leading Platform with Suite of Automated Supply and Medication Management Solutions at AHRMM18
August 15, 2018
Read more...

Ratios

vs
industry		 vs
history
PE Ratio 58.92
OMCL's PE Ratio is ranked lower than
79% of the 1281 Companies
in the Global Health Information Services industry.

( Industry Median: 27.75 vs. OMCL: 58.92 )
Ranked among companies with meaningful PE Ratio only.
OMCL' s PE Ratio Range Over the Past 10 Years
Min: 8.9  Med: 44.33 Max: 1930
Current: 58.92
8.9
1930
Forward PE Ratio 26.88
OMCL's Forward PE Ratio is ranked lower than
63% of the 343 Companies
in the Global Health Information Services industry.

( Industry Median: 25.00 vs. OMCL: 26.88 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 58.92
OMCL's PE Ratio without NRI is ranked lower than
79% of the 1278 Companies
in the Global Health Information Services industry.

( Industry Median: 27.79 vs. OMCL: 58.92 )
Ranked among companies with meaningful PE Ratio without NRI only.
OMCL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.9  Med: 44.33 Max: 1930
Current: 58.92
8.9
1930
Price-to-Owner-Earnings 139.44
OMCL's Price-to-Owner-Earnings is ranked lower than
99.99% of the 760 Companies
in the Global Health Information Services industry.

( Industry Median: 28.11 vs. OMCL: 139.44 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
OMCL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.6  Med: 37.79 Max: 466.06
Current: 139.44
7.6
466.06
PB Ratio 4.14
OMCL's PB Ratio is ranked lower than
62% of the 1858 Companies
in the Global Health Information Services industry.

( Industry Median: 3.12 vs. OMCL: 4.14 )
Ranked among companies with meaningful PB Ratio only.
OMCL' s PB Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.36 Max: 4.9
Current: 4.14
0.96
4.9
PS Ratio 3.44
OMCL's PS Ratio is ranked lower than
59% of the 1840 Companies
in the Global Health Information Services industry.

( Industry Median: 2.60 vs. OMCL: 3.44 )
Ranked among companies with meaningful PS Ratio only.
OMCL' s PS Ratio Range Over the Past 10 Years
Min: 0.94  Med: 2.16 Max: 4.08
Current: 3.44
0.94
4.08
Price-to-Free-Cash-Flow 73.72
OMCL's Price-to-Free-Cash-Flow is ranked lower than
99% of the 750 Companies
in the Global Health Information Services industry.

( Industry Median: 30.05 vs. OMCL: 73.72 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
OMCL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.02  Med: 28.55 Max: 1108.87
Current: 73.72
8.02
1108.87
Price-to-Operating-Cash-Flow 43.45
OMCL's Price-to-Operating-Cash-Flow is ranked lower than
90% of the 923 Companies
in the Global Health Information Services industry.

( Industry Median: 21.70 vs. OMCL: 43.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OMCL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 20.49 Max: 10100
Current: 43.45
6.98
10100
EV-to-EBIT 66.40
OMCL's EV-to-EBIT is ranked lower than
88% of the 1311 Companies
in the Global Health Information Services industry.

( Industry Median: 19.89 vs. OMCL: 66.40 )
Ranked among companies with meaningful EV-to-EBIT only.
OMCL' s EV-to-EBIT Range Over the Past 10 Years
Min: -224.8  Med: 23.4 Max: 423.3
Current: 66.4
-224.8
423.3
EV-to-EBITDA 29.82
OMCL's EV-to-EBITDA is ranked lower than
72% of the 1413 Companies
in the Global Health Information Services industry.

( Industry Median: 15.96 vs. OMCL: 29.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMCL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.7  Med: 15.7 Max: 53
Current: 29.82
3.7
53
EV-to-Revenue 3.53
OMCL's EV-to-Revenue is ranked lower than
58% of the 1910 Companies
in the Global Health Information Services industry.

( Industry Median: 2.65 vs. OMCL: 3.53 )
Ranked among companies with meaningful EV-to-Revenue only.
OMCL' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 1.9 Max: 4.3
Current: 3.53
0.4
4.3
PEG Ratio 12.96
OMCL's PEG Ratio is ranked lower than
92% of the 599 Companies
in the Global Health Information Services industry.

( Industry Median: 2.07 vs. OMCL: 12.96 )
Ranked among companies with meaningful PEG Ratio only.
OMCL' s PEG Ratio Range Over the Past 10 Years
Min: 0.5  Med: 2.32 Max: 358.8
Current: 12.96
0.5
358.8
Shiller PE Ratio 136.43
OMCL's Shiller PE Ratio is ranked lower than
91% of the 434 Companies
in the Global Health Information Services industry.

( Industry Median: 37.98 vs. OMCL: 136.43 )
Ranked among companies with meaningful Shiller PE Ratio only.
OMCL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 36.8  Med: 59.22 Max: 160.9
Current: 136.43
36.8
160.9
Current Ratio 1.78
OMCL's Current Ratio is ranked lower than
54% of the 1957 Companies
in the Global Health Information Services industry.

( Industry Median: 1.93 vs. OMCL: 1.78 )
Ranked among companies with meaningful Current Ratio only.
OMCL' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.18 Max: 5.21
Current: 1.78
0.64
5.21
Quick Ratio 1.32
OMCL's Quick Ratio is ranked lower than
69% of the 1957 Companies
in the Global Health Information Services industry.

( Industry Median: 1.79 vs. OMCL: 1.32 )
Ranked among companies with meaningful Quick Ratio only.
OMCL' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.85 Max: 4.95
Current: 1.32
0.4
4.95
Days Inventory 88.18
OMCL's Days Inventory is ranked lower than
83% of the 1137 Companies
in the Global Health Information Services industry.

( Industry Median: 16.22 vs. OMCL: 88.18 )
Ranked among companies with meaningful Days Inventory only.
OMCL' s Days Inventory Range Over the Past 10 Years
Min: 35.45  Med: 55.69 Max: 88.18
Current: 88.18
35.45
88.18
Days Sales Outstanding 97.31
OMCL's Days Sales Outstanding is ranked lower than
64% of the 1879 Companies
in the Global Health Information Services industry.

( Industry Median: 68.11 vs. OMCL: 97.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMCL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.2  Med: 69.97 Max: 97.31
Current: 97.31
56.2
97.31
Days Payable 34.30
OMCL's Days Payable is ranked lower than
64% of the 1720 Companies
in the Global Health Information Services industry.

( Industry Median: 45.50 vs. OMCL: 34.30 )
Ranked among companies with meaningful Days Payable only.
OMCL' s Days Payable Range Over the Past 10 Years
Min: 26.08  Med: 34.86 Max: 46.45
Current: 34.3
26.08
46.45

Buy Back

vs
industry		 vs
history
3-Year Average Share Buyback Ratio -2.40
OMCL's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 1387 Companies
in the Global Health Information Services industry.

( Industry Median: -3.30 vs. OMCL: -2.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMCL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.8  Med: -2.6 Max: 1.6
Current: -2.4
-140.8
1.6

Valuation & Return

vs
industry		 vs
history
Price-to-Tangible-Book 31.90
OMCL's Price-to-Tangible-Book is ranked lower than
96% of the 1555 Companies
in the Global Health Information Services industry.

( Industry Median: 4.26 vs. OMCL: 31.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OMCL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 5.62 Max: 52.73
Current: 31.9
1.2
52.73
Price-to-Intrinsic-Value-Projected-FCF 2.79
OMCL's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
63% of the 840 Companies
in the Global Health Information Services industry.

( Industry Median: 2.11 vs. OMCL: 2.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OMCL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.46 Max: 12.74
Current: 2.79
0.94
12.74
Price-to-Intrinsic-Value-DCF (Earnings Based) 5.51
OMCL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
89% of the 176 Companies
in the Global Health Information Services industry.

( Industry Median: 1.83 vs. OMCL: 5.51 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
OMCL' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 3.3  Med: 4.66 Max: 161.43
Current: 5.51
3.3
161.43
Price-to-Median-PS-Value 1.60
OMCL's Price-to-Median-PS-Value is ranked lower than
73% of the 1656 Companies
in the Global Health Information Services industry.

( Industry Median: 1.09 vs. OMCL: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OMCL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.06 Max: 2.28
Current: 1.6
0.23
2.28
Price-to-Graham-Number 9.13
OMCL's Price-to-Graham-Number is ranked lower than
95% of the 974 Companies
in the Global Health Information Services industry.

( Industry Median: 2.25 vs. OMCL: 9.13 )
Ranked among companies with meaningful Price-to-Graham-Number only.
OMCL' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.33  Med: 3.05 Max: 10.82
Current: 9.13
1.33
10.82
Earnings Yield (Greenblatt) % 1.50
OMCL's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 2008 Companies
in the Global Health Information Services industry.

( Industry Median: 2.11 vs. OMCL: 1.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OMCL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.8  Med: 3.9 Max: 19
Current: 1.5
-0.8
19
Forward Rate of Return (Yacktman) % 0.69
OMCL's Forward Rate of Return (Yacktman) % is ranked lower than
72% of the 833 Companies
in the Global Health Information Services industry.

( Industry Median: 9.82 vs. OMCL: 0.69 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
OMCL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.2  Med: 21.7 Max: 25
Current: 0.69
-0.2
25

More Statistics

Revenue (TTM) (Mil) $773.50
EPS (TTM) $ 1.11
Beta1.65
Volatility36.68%
52-Week Range $39.75 - 79.48
Shares Outstanding (Mil)39.63

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 793 880 979
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 0.96 1.28 1.73
EPS without NRI ($) 0.96 1.28 1.73
EPS Growth Rate
(Future 3Y To 5Y Estimate)		 2.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

» More Articles for OMCL

Headlines

Articles On GuruFocus.com
Omnicell To Present At The 37th Annual J.P. Morgan Healthcare Conference Dec 27 2018 
Northeast Georgia Health System Selects Omnicell Automated Medication Management Platform to Support Dec 05 2018 
Omnicell Launches Vision for Fully Digitized, Autonomous Pharmacy at Annual ASHP Midyear Meeting Dec 03 2018 
Omnicell To Present At The 30th Annual Piper Jaffray Healthcare Conference Nov 14 2018 
Market Trends Toward New Normal in M/I Homes, Omnicell, Allegheny Technologies, S&P Global, First So Oct 30 2018 
Omnicell to Release Third Quarter 2018 Earnings Results on October 25, 2018 Oct 18 2018 
Augusta University Health Selects Omnicell's Industry-Leading Medication Management Portfolio to Sup Oct 10 2018 
Middlesex Hospital Bolsters Pharmacy Safety and Compliance by Extending Wolters Kluwer's Simplifi 79 Sep 18 2018 
Rob Seim to retire and join Omnicell Board of Directors Sep 14 2018 
Innovations to Omnicell Patient Engagement Platform Support Value-Based, Patient-Centered Care Aug 23 2018 

More From Our Partners
CVS Health's PBM Pharmacy Platform to Ride on Walmart Deal Jan 22 2019 - ZACKS

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}